Acute Myeloid Leukemia, Adult Clinical Trial
Official title:
Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition, Muscle Strength and Concentration of Vascular Endothelial Growth Factor (VEGF) in Patients With Actue Myeloid Leukemia (AML) During the Hospital Stay
A randomized controlled clinical trial in two groups of supplementation with high protein enteral formula and a normocaloric enteral formula in two groups of 37 patients .
Patients with acute myeloid leukemia have a high risk of suffering sarcopenia, which
decreases the oncology therapy clinical response, functional ability and quality of life.
Chemotherapy is used in these patients, some of them inhibit angiogenesis and act in an
important way in physiological processes of muscle anabolism. The vascular endothelial growth
factor (VEGF) and its receptors (VEGFR) play a crucial role in both normal and malignant
angiogenesis. Activation of the VEGF pathway leads to endothelial cell activation,
proliferation and survival.
The objective of this study is to compare the effect of the use of a high protein, high
energy enteral with omega 3 formula (Supportan DKN) against a standard enteral formula
(Fresubin® Original DRINK) on body composition, days of hospital stay, quality of life,
associated muscular strength with levels of VEGF in patients with acute myeloid leukemia
during induction chemotherapy.
An open clinical trial was designed, in which a group of patients will receive, as part of
their nutritional requirements a hyperproteic hyperenergetic enteral formula versus standard
formula during the 21 days of the first cycle of antineoplastic treatment. We will measure
body composition, muscle strength and serum concentrations of VEGFR in both groups to be able
to compare its effect.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05133882 -
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05601726 -
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
|
Phase 1 | |
| Recruiting |
NCT06200441 -
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
|
||
| Recruiting |
NCT04050280 -
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
|
Phase 2 | |
| Recruiting |
NCT06449482 -
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06252584 -
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
|
Phase 1 | |
| Completed |
NCT05988047 -
Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia
|
||
| Terminated |
NCT03951961 -
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
|
Phase 2 | |
| Enrolling by invitation |
NCT03902665 -
Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75
|
Phase 2 | |
| Not yet recruiting |
NCT06285136 -
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05127798 -
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
|
||
| Recruiting |
NCT05906914 -
Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia
|
Phase 2 | |
| Not yet recruiting |
NCT06199557 -
A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04752527 -
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
|
Phase 2 | |
| Recruiting |
NCT03766126 -
Lentivirally Redirected CD123 Autologous T Cells in AML
|
Phase 1 | |
| Recruiting |
NCT05674539 -
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
Phase 3 | |
| Enrolling by invitation |
NCT02985372 -
Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia
|
Phase 3 | |
| Recruiting |
NCT05703126 -
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML
|
N/A | |
| Terminated |
NCT04425655 -
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
|
Phase 2 | |
| Recruiting |
NCT04454580 -
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
|